Filing Flows › Ginkgo Bioworks Holdings (DNA) › Q3 2025
Ginkgo Bioworks Holdings (DNA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Ginkgo Bioworks Holdings (DNA) reported revenue of $38.8M for the third quarter 2025 (Q3 2025), -56% from a year earlier and -22% from the quarter before. Operating margin was -231.8%, net loss $80.8M (207.9% of revenue).
Ginkgo Bioworks Holdings, Q3 2025: revenue $38.8M (-56% year over year), operating margin -231.8%, net loss $80.8M, operating cash flow −$31.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $38.8M | -22% | -56% |
| Operating profit | −$90.0M | — | — |
| Net earnings | −$80.8M | — | — |
| Operating cash flow | −$31.6M | — | — |
What changed
Revenue was $38.8M in Q3 2025, down 56% year over year and down 22% from the previous quarter. Cell Engineering was the largest line at 76% of revenue. Cell Engineering lost $45.7M year over year (down 61%), 91% of the total change.
Operating costs exceeded revenue by $90.0M, an operating margin of -231.8%. Total costs fell 11% while revenue fell 56%. The quarter ended with a net loss of $80.8M, wider than the previous quarter's $60.3M loss.
Operating cash flow was −$31.6M. Non-cash charges added back $15.3M of depreciation and amortization and $17.8M of share-based compensation. Working capital and other items added $16.1M.
Questions
What was Ginkgo Bioworks Holdings' revenue in the third quarter 2025?
Ginkgo Bioworks Holdings (DNA) reported revenue of $38.8M for the third quarter 2025 (Q3 2025), -56% from a year earlier and -22% from the quarter before.
Was Ginkgo Bioworks Holdings profitable in the third quarter 2025?
Operating loss was $90.0M (-231.8% of revenue) and net loss $80.8M.